KMT2A and acute myeloid leukemia: MOF was identified in an shRNA library screen (2252 shRNAs targeting 468 chromatin regulators) aimed at finding novel druggable targets in the epigenetic pathways that maintain AML driven by MLL-AF9, a type of MLL-r characterized by the translocation of MLL1 and AF9 genes [13].